Reversible Parkinsonism linked to trimetazidine (continued).
Identifieur interne : 000E16 ( PubMed/Curation ); précédent : 000E15; suivant : 000E17Reversible Parkinsonism linked to trimetazidine (continued).
Auteurs :Source :
- Prescrire international [ 1167-7422 ] ; 2006.
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- France, Humans, Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (physiopathology), Treatment Outcome, Trimetazidine (administration & dosage), Trimetazidine (adverse effects), Trimetazidine (therapeutic use), Vasodilator Agents (administration & dosage), Vasodilator Agents (adverse effects), Vasodilator Agents (therapeutic use).
- MESH :
- chemical , administration & dosage : Trimetazidine, Vasodilator Agents.
- chemical , adverse effects : Trimetazidine, Vasodilator Agents.
- chemical , therapeutic use : Trimetazidine, Vasodilator Agents.
- geographic : France.
- chemically induced : Parkinson Disease, Secondary.
- physiopathology : Parkinson Disease, Secondary.
- Humans, Treatment Outcome.
Abstract
(1) In a series of 128 neurological patients taking trimetazidine, 56 developed motor disorders that improved or resolved when trimetazidine was withdrawn. (2) New cases of parkinsonism, gait disorders and tremor that resolved or improved after trimetazidine withdrawal have been reported in France. (3) As there is no evidence that trimetazidine is effective, there is no justification for placing patients at risk for parkinsonism. (4) Patients who develop motor disorders while taking trimetazidine have everything to gain and nothing to lose by discontinuing treatment. There is no possible justification for initiating treatment with trimetazidine.
PubMed: 16989026
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E56
Links to Exploration step
pubmed:16989026Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reversible Parkinsonism linked to trimetazidine (continued).</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16989026</idno><idno type="pmid">16989026</idno><idno type="wicri:Area/PubMed/Corpus">000E56</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E56</idno><idno type="wicri:Area/PubMed/Curation">000E16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Reversible Parkinsonism linked to trimetazidine (continued).</title></analytic><series><title level="j">Prescrire international</title><idno type="ISSN">1167-7422</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>France</term><term>Humans</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (physiopathology)</term><term>Treatment Outcome</term><term>Trimetazidine (administration & dosage)</term><term>Trimetazidine (adverse effects)</term><term>Trimetazidine (therapeutic use)</term><term>Vasodilator Agents (administration & dosage)</term><term>Vasodilator Agents (adverse effects)</term><term>Vasodilator Agents (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Trimetazidine</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Trimetazidine</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Trimetazidine</term><term>Vasodilator Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">(1) In a series of 128 neurological patients taking trimetazidine, 56 developed motor disorders that improved or resolved when trimetazidine was withdrawn. (2) New cases of parkinsonism, gait disorders and tremor that resolved or improved after trimetazidine withdrawal have been reported in France. (3) As there is no evidence that trimetazidine is effective, there is no justification for placing patients at risk for parkinsonism. (4) Patients who develop motor disorders while taking trimetazidine have everything to gain and nothing to lose by discontinuing treatment. There is no possible justification for initiating treatment with trimetazidine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="HSR"><PMID Version="1">16989026</PMID><DateCreated><Year>2006</Year><Month>09</Month><Day>21</Day></DateCreated><DateCompleted><Year>2006</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1167-7422</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>84</Issue><PubDate><Year>2006</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Prescrire international</Title><ISOAbbreviation>Prescrire Int</ISOAbbreviation></Journal><ArticleTitle>Reversible Parkinsonism linked to trimetazidine (continued).</ArticleTitle><Pagination><MedlinePgn>136</MedlinePgn></Pagination><Abstract><AbstractText>(1) In a series of 128 neurological patients taking trimetazidine, 56 developed motor disorders that improved or resolved when trimetazidine was withdrawn. (2) New cases of parkinsonism, gait disorders and tremor that resolved or improved after trimetazidine withdrawal have been reported in France. (3) As there is no evidence that trimetazidine is effective, there is no justification for placing patients at risk for parkinsonism. (4) Patients who develop motor disorders while taking trimetazidine have everything to gain and nothing to lose by discontinuing treatment. There is no possible justification for initiating treatment with trimetazidine.</AbstractText></Abstract><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Prescrire Int</MedlineTA><NlmUniqueID>9439295</NlmUniqueID><ISSNLinking>1167-7422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>N9A0A0R9S8</RegistryNumber><NameOfSubstance UI="D014292">Trimetazidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014292" MajorTopicYN="N">Trimetazidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16989026</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000E16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16989026
|texte= Reversible Parkinsonism linked to trimetazidine (continued).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16989026" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |